---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Dosage forms and strengths"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Dosage forms and strengths. Topics: Pharmaceutical form and route of administration, Pharmaceutical form and concentrations in the European phase Ib/II study, Dose levels administered in the phase I/II studies: vector genomes per participant, and Administration device: stereotactic MRI-guided cannula. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/dosage-forms-and-strengths"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Dosage forms and strengths

<a id="heading-2.1.2.2"></a>

## 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

### Pharmaceutical form and route of administration

| Field | Quoted record |
| --- | --- |
| Active substance | “ifezuntirgene inilparvovec” |
| Condition | “Treatment of Huntington’s disease” |
| Pharmaceutical form | “Suspension for infusion” |
| Route of administration | “INTRACEREBRAL USE” |
| Applicant | “uniQure biopharma B.V.” |

Source: [MHRA paediatric investigation plan waiver decision (2026)](https://cms.mhra.gov.uk//system/files/2026-07/mhra-102322-pip01-26.pdf)

<a id="topic-2.1.2.2-2"></a>

### Pharmaceutical form and concentrations in the European phase Ib/II study

| Field | Quoted record |
| --- | --- |
| Pharmaceutical form | “Solution for infusion” |
| Concentration, first IMP | “2 x 10e12 gc/mL” |
| Concentration, second IMP | “2 x 10e13 gc/mL” |

Source: [EU Clinical Trials Register 2020-001461-36](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001461-36/PL)

<a id="topic-2.1.2.2-3"></a>

### Dose levels administered in the phase I/II studies: vector genomes per participant

> “AMT-130 was generally well tolerated in the treated patients at the lower dose of 6x1012 vector genomes (vg).”
> “The safety profile of AMT-130 in the low-dose cohort to date supports continued enrollment of patients in the higher-dose cohort of 6x1013 vg.”

Source: [uniQure press release, clinical update on first patients (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-clinical-update-first-patients-phase-iii)

<a id="topic-2.1.2.2-4"></a>

### Administration device: stereotactic MRI-guided cannula

> “Certain of our product candidates require medical devices for administration, such as AMT-130 and AMT-260, each of which requires a stereotactic, magnetic resonance imaging guided cannula.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.1.2.2-5"></a>

### Formulation composition, fill volume, and storage conditions

No evidence found.

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
